A detailed history of Schonfeld Strategic Advisors LLC transactions in Infla Rx N.V. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 18,100 shares of IFRX stock, worth $46,698. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,100
Previous 20,100 9.95%
Holding current value
$46,698
Previous $34,000 20.59%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.34 - $1.73 $2,680 - $3,460
-2,000 Reduced 9.95%
18,100 $27,000
Q2 2024

Aug 14, 2024

SELL
$1.18 - $1.74 $6,608 - $9,744
-5,600 Reduced 21.79%
20,100 $34,000
Q1 2024

May 15, 2024

SELL
$1.47 - $2.03 $2,940 - $4,059
-2,000 Reduced 7.22%
25,700 $39,000
Q4 2023

Feb 14, 2024

SELL
$1.25 - $2.75 $429,402 - $944,685
-343,522 Reduced 92.54%
27,700 $45,000
Q3 2023

Nov 14, 2023

BUY
$2.66 - $4.33 $5,929 - $9,651
2,229 Added 0.6%
371,222 $1.11 Million
Q2 2023

Aug 14, 2023

BUY
$2.05 - $6.1 $756,435 - $2.25 Million
368,993 New
368,993 $1.65 Million
Q1 2021

May 17, 2021

SELL
$3.62 - $6.34 $113,306 - $198,442
-31,300 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$3.82 - $5.32 $677,289 - $943,241
-177,301 Reduced 85.0%
31,300 $158,000
Q3 2020

Nov 16, 2020

BUY
$3.7 - $5.47 $641,435 - $948,284
173,361 Added 491.94%
208,601 $1,000
Q2 2020

Aug 14, 2020

BUY
$4.59 - $8.96 $62,676 - $122,348
13,655 Added 63.26%
35,240 $162,000
Q1 2020

May 15, 2020

BUY
$2.65 - $6.08 $57,200 - $131,236
21,585 New
21,585 $82,000

Others Institutions Holding IFRX

About InflaRx N.V.


  • Ticker IFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,203,800
  • Market Cap $114M
  • Description
  • InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...
More about IFRX
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.